勵晶太平洋(00575.HK):Fortacin營銷授權由處方藥轉為非處方藥以大幅提升銷量
格隆匯9月3日丨勵晶太平洋(00575.HK)公告,RecordatiS.p.A.已於2020年8月27日獲得歐盟委員會的批准,Fortacin的營銷授權由處方藥轉為非處方藥地位。轉為非處方藥旨在大幅提升銷量以及繼而增加支付給集團的專利權使用費。Recordati曾提及其擬自2021年1月起開始推出非處方藥,前提是其已取得任何所需的國家批文(如需要)及生產商Pharmaserve (NorthWest) Limited能滿足估計增長的需求,以及2019冠狀病毒病疫情不會進一步耽誤或妨礙如期推出非處方藥。
Recordati、PSNW及集團正在探討擴大生產規模的各種方案,以滿足估計對非處方藥的需求,目標是每批量訂單生產約50,000單位,並減少供應鏈短缺及不可靠的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.